June 13, 2024
Sarcopenia Treatment Market

Sarcopenia Treatment Market Poised for High Growth with Aging Population

The sarcopenia treatment market has been witnessing significant growth over the past few years on account of rising geriatric population worldwide. Sarcopenia refers to the loss of skeletal muscle mass and strength associated with aging. Some key products available in the market for sarcopenia treatment include protein supplements, vitamin D and mineral supplements, and exercise therapy equipment. Protein supplements help in increasing protein intake which is important for muscle growth and repair. Vitamin D and mineral supplements assist in improving muscle function. Exercise equipment like dumbbells, barbells and treadmills are utilized for resistance training and strength building exercises.

The Global sarcopenia treatment market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period from 2024 to 2031.

Key Takeaways

The market provides lucrative opportunities for players engaged in new product development and launches. Companies are focusing on developing more effective nutraceuticals, biomarkers and anabolic agents for Sarcopenia Treatment Market Size. Growing aging population worldwide will drive the demand for sarcopenia treatment over the next decade.

Key players operating in the sarcopenia treatment market are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology.

The global sarcopenia treatment market is expected to witness high growth in the Asia Pacific region owing to increasing senior citizen population countries like China, India and Japan. North America and Europe currently dominate the market due to high disposable incomes and healthcare spending.

Market Drivers

The major factor driving the growth of Sarcopenia Treatment Market Size is increase in global geriatric population. According to United Nations data, over 700 million people will be aged 65 years and above globally by 2025. Sarcopenia is highly prevalent among old adults beyond 60 years of age. Rising awareness regarding sarcopenia condition and its available treatment options is also boosting the market growth. Moreover, introduction of innovative treatment products by leading players will further fuel the sarcopenia treatment industry in coming years.

PEST Analysis

Political: The healthcare policies and regulations influence research funding and drug approvals for sarcopenia treatment. Additionally, regulations regarding the aging population will impact demand for sarcopenia medication and therapies.

Economic: Rising healthcare expenditures and growing geriatric population globally are major drivers for growth of sarcopenia treatment market. However, economic uncertainties can slow down the market expansion.

Social: Extended life expectancy and lifestyle changes resulting in poor nutrition and lack of physical activity have increased the risk of sarcopenia. This along with increasing health awareness boosts the market.

Technological: Advancements in diagnostics aids early detection of sarcopenia. Development of novel targeted therapies, supplements, and nutraceuticals helps address the unmet needs in sarcopenia treatment.

The North American region currently holds the major share of sarcopenia treatment market in terms of value due to factors such as high healthcare spending, major drug launches, and massive elderly population. The United States alone accounts for over 30% share of the total market.

The Asia Pacific region is projected to be the fastest growing market during the forecast period. This growth can be attributed to rising geriatric population, improving healthcare infrastructure, growing awareness about sarcopenia, and increasing focus of key players on emerging Asian countries. China and Japan have large senior populace vulnerable to sarcopenia, creating lucrative opportunities in this region.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it